10-Q: Intelligent Bio Solutions Reports Q3 2026 Results, Revenue Up 46%

Intelligent Bio Solutions Inc. announced its third-quarter fiscal year 2026 results, showcasing a 46% year-over-year revenue increase driven by new customer acquisition and strong re-order rates for consumables.

Summary

• Intelligent Bio Solutions Inc. reported a 46% increase in revenue for the three months ended March 31, 2026, reaching $1,060,802, compared to $728,867 in the prior year period.
• The nine-month revenue also saw a 39% increase, totaling $3,069,373 for the period ended March 31, 2026.
• Gross profit for the quarter rose by $194,013 to $535,381, with gross margin improving to 50.47% from 46.84%.
• The company reported a net loss of $2,862,712 for the three months ended March 31, 2026.
• Significant capital raises occurred, including a $10 million private placement in January 2026 and ongoing ATM offerings.
• The company continues to face going concern risks, with a need to raise additional funds within the next 12 months.
• Development and regulatory approval expenses increased significantly, driven by clinical studies for FDA submission.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive sentiment, with strong revenue growth offset by continued net losses and going concern risks.

Positives

• Revenue increased by 46% to $1,060,802 for the three months ended March 31, 2026, compared to $728,867 in the prior year.
• Nine-month revenue increased by 39% to $3,069,373 for the period ended March 31, 2026.
• Gross profit increased by $194,013 to $535,381 for the three months ended March 31, 2026.
• Gross margin improved to 50.47% for the three months ended March 31, 2026, from 46.84% in the prior year.
• Contribution margin percentage improved to 74.50% for the three months ended March 31, 2026, from 73.18% in the prior year.
• Received European Patent EP3752831 related to fingerprint chemical analysis.
• Secured a strategic manufacturing partnership with Syrma Johari MedTech Ltd.
• Announced a partnership with Bouygues UK for deployment of fingerprint drug screening technology.

Negatives

• Net loss for the three months ended March 31, 2026, was $2,862,712.
• Net loss for the nine months ended March 31, 2026, was $8,523,308.
• Development and regulatory approval expenses increased by $535,628 to $893,979 for the three months ended March 31, 2026.
• The company has evaluated that there is a material risk that its cash and cash equivalents may be insufficient to fund its operating plan for the next 12 months.
• The company will be required to raise additional funds during the next 12 months.
• There is a risk of extended delays in negotiating licensing terms for intellectual property with the University of Newcastle.
• The company may not be able to repay the grant received from the Australian Government when due, with $1,513,290 remaining payable.

Risks

• The company may not be able to satisfy the continued listing requirements of the Nasdaq Capital Market.
• Changes in government funding levels, staffing resources, or policy priorities at the FDA, SEC, and other government agencies could adversely affect their ability to perform their regulatory and oversight functions.
• The company will need to raise additional capital to fund its operations, and there is no assurance that such capital will be available on favorable terms or at all.
• The company may not be able to repay the grant it received from the Australian Government when due.
• The liquidation of LSBD and the potential for extended delays in negotiating licensing terms for intellectual property with the University of Newcastle could negatively impact the company's ability to develop and commercialize its products.
• The loss of emerging growth company status will increase reporting and compliance obligations.

Future Outlook

The company expects revenue growth to continue as it expands into new markets. Development and regulatory expenses are expected to increase as the company works towards FDA submission. Management believes there is a material risk that current cash and cash equivalents will be insufficient to fund the operating plan for the next 12 months, necessitating additional fundraising.

Management Comments

• Gross profit margin improvement during the period was driven by a combination of operational efficiencies and increased sales volumes, alongside a value-driven price structure that has remained consistent as customers recognize the superior efficiency and ROI of our fingerprint sweat screening technology over traditional methods.
• The company believes marketing expenditure has achieved objectives through increased revenue and successful capital raising.
• Management believes there is a material risk that its cash and cash equivalents as of March 31, 2026, may be insufficient to allow the Company to fund its current operating plan through at least the next twelve months.

Industry Context

StockSavvy.ai notes that Intelligent Bio Solutions Inc. is operating in the competitive medical technology and diagnostics sector, with a focus on non-invasive drug screening. The company's revenue growth is a positive sign, but the increasing development and regulatory expenses highlight the capital-intensive nature of bringing new diagnostic tools to market, particularly in the US with FDA clearance being a key hurdle.

Comparison to Industry Standards

• The company's gross margin of 50.47% for the quarter is strong, but direct comparison to industry peers is difficult without specific data on competitors' gross margins for similar non-invasive drug screening technologies.
• The increase in SG&A expenses, particularly marketing and investor relations, aligns with companies seeking to expand market awareness and support capital raising efforts in the biotech/medtech sector.
• The significant investment in R&D and regulatory approval expenses is typical for companies pursuing FDA clearance for novel medical devices.

Legal Proceedings

• The company is not currently engaged in any material legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution from future equity or debt financings.
• The company's ability to continue as a going concern may impact shareholder value.
• Employees may be affected by potential delays or reductions in the scope of operations if funding is not secured.
• Suppliers and creditors may face risks if the company cannot meet its financial obligations.

Next Steps

• Continue to expand market share across the United Kingdom and mainland Europe.
• Expand sales and distribution throughout the Asia Pacific Region.
• Continue to gather additional supporting data for the FDA 510(k) submission.
• Initiate research to broaden IFP System capabilities for additional drugs and indications.
• Expand IFP System into new customer segments like sporting organizations, law enforcement, and commercial airlines.
• Develop a strategic network of distributors in APAC, Europe, and North America.
• Raise additional funds within the next 12 months to support operations.

Key Dates

Recommendation

The company shows promising revenue growth and technological advancements, but the significant net losses, ongoing need for capital raises, and going concern risks necessitate a cautious approach. Investors should monitor progress on FDA clearance and future fundraising efforts.

Keywords

Intelligent Bio Solutions, SEC Filing, 10-Q Report, Financial Results, Drug Screening, Fingerprint Technology, Medical Technology, Revenue Growth